A citation-based method for searching scientific literature


List of co-cited articles
720 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
75

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
819
46


Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk S J Opstal, Salem H K The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink,[...]. N Engl J Med 2020
384
25

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Paul M Ridker, Brendan M Everett, Aruna Pradhan, Jean G MacFadyen, Daniel H Solomon, Elaine Zaharris, Virak Mam, Ahmed Hasan, Yves Rosenberg, Erin Iturriaga,[...]. N Engl J Med 2019
526
24

Low-dose colchicine for secondary prevention of cardiovascular disease.
Stefan M Nidorf, John W Eikelboom, Charley A Budgeon, Peter L Thompson. J Am Coll Cardiol 2013
468
23

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Peter Duewell, Hajime Kono, Katey J Rayner, Cherilyn M Sirois, Gregory Vladimer, Franz G Bauernfeind, George S Abela, Luigi Franchi, Gabriel Nuñez, Max Schnurr,[...]. Nature 2010
23

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Yiran Guo, Christina Chung, Anne Peasey, Roman Pfister,[...]. Lancet 2012
637
19

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Paul M Ridker, Peter Libby, Jean G MacFadyen, Tom Thuren, Christie Ballantyne, Francisco Fonseca, Wolfgang Koenig, Hiroaki Shimokawa, Brendan M Everett, Robert J Glynn. Eur Heart J 2018
219
18

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
18


The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
Allison C Morton, Alexander M K Rothman, John P Greenwood, Julian Gunn, Alex Chase, Bernard Clarke, Alistair S Hall, Keith Fox, Claire Foley, Winston Banya,[...]. Eur Heart J 2015
169
17




The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
Gerardus P J van Hout, Lena Bosch, Guilielmus H J M Ellenbroek, Judith J de Haan, Wouter W van Solinge, Matthew A Cooper, Fatih Arslan, Saskia C A de Jager, Avril A B Robertson, Gerard Pasterkamp,[...]. Eur Heart J 2017
188
14

NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Alena Grebe, Florian Hoss, Eicke Latz. Circ Res 2018
266
14

The NLRP3 inflammasome: molecular activation and regulation to therapeutics.
Karen V Swanson, Meng Deng, Jenny P-Y Ting. Nat Rev Immunol 2019
14

Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Ola Kleveland, Gabor Kunszt, Marte Bratlie, Thor Ueland, Kaspar Broch, Espen Holte, Annika E Michelsen, Bjørn Bendz, Brage H Amundsen, Terje Espevik,[...]. Eur Heart J 2016
168
13

NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
Thomas van der Heijden, Eva Kritikou, Wouter Venema, Janine van Duijn, Peter J van Santbrink, Bram Slütter, Amanda C Foks, Ilze Bot, Johan Kuiper. Arterioscler Thromb Vasc Biol 2017
163
13

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.
Siddhartha Jaiswal, Pradeep Natarajan, Alexander J Silver, Christopher J Gibson, Alexander G Bick, Eugenia Shvartz, Marie McConkey, Namrata Gupta, Stacey Gabriel, Diego Ardissino,[...]. N Engl J Med 2017
942
12

C-reactive protein levels and outcomes after statin therapy.
Paul M Ridker, Christopher P Cannon, David Morrow, Nader Rifai, Lynda M Rose, Carolyn H McCabe, Marc A Pfeffer, Eugene Braunwald. N Engl J Med 2005
12


Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Nadeem Sarwar, Adam S Butterworth, Daniel F Freitag, John Gregson, Peter Willeit, Donal N Gorman, Pei Gao, Danish Saleheen, Augusto Rendon, Christopher P Nelson,[...]. Lancet 2012
500
12

Atherosclerosis.
Peter Libby, Julie E Buring, Lina Badimon, Göran K Hansson, John Deanfield, Márcio Sommer Bittencourt, Lale Tokgözoğlu, Eldrin F Lewis. Nat Rev Dis Primers 2019
570
11

The NLRP3 inflammasome in acute myocardial infarction.
Stefano Toldo, Antonio Abbate. Nat Rev Cardiol 2018
250
11

Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
Brendan M Everett, Jan H Cornel, Mitja Lainscak, Stefan D Anker, Antonio Abbate, Tom Thuren, Peter Libby, Robert J Glynn, Paul M Ridker. Circulation 2019
210
11

Gout-associated uric acid crystals activate the NALP3 inflammasome.
Fabio Martinon, Virginie Pétrilli, Annick Mayor, Aubry Tardivel, Jürg Tschopp. Nature 2006
11

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
Nadia Bouabdallaoui, Jean-Claude Tardif, David D Waters, Fausto J Pinto, Aldo P Maggioni, Rafael Diaz, Colin Berry, Wolfgang Koenig, Jose Lopez-Sendon, Habib Gamra,[...]. Eur Heart J 2020
80
11

Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Antonio Abbate, Stefano Toldo, Carlo Marchetti, Jordana Kron, Benjamin W Van Tassell, Charles A Dinarello. Circ Res 2020
135
11

Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy.
Tjerk S J Opstal, Renate M Hoogeveen, Aernoud T L Fiolet, Max J M Silvis, Salem H K The, Willem A Bax, Dominique P V de Kleijn, Arend Mosterd, Erik S G Stroes, Jan H Cornel. Circulation 2020
46
19

Inflammation in atherosclerosis.
Peter Libby. Arterioscler Thromb Vasc Biol 2012
9

Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis.
Stephen Kaptoge, Sreenivasa Rao Kondapally Seshasai, Pei Gao, Daniel F Freitag, Adam S Butterworth, Anders Borglykke, Emanuele Di Angelantonio, Vilmundur Gudnason, Ann Rumley, Gordon D O Lowe,[...]. Eur Heart J 2014
339
9

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.
José J Fuster, Susan MacLauchlan, María A Zuriaga, Maya N Polackal, Allison C Ostriker, Raja Chakraborty, Chia-Ling Wu, Soichi Sano, Sujatha Muralidharan, Cristina Rius,[...]. Science 2017
583
9

Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
Benjamin W Van Tassell, Justin Canada, Salvatore Carbone, Cory Trankle, Leo Buckley, Claudia Oddi Erdle, Nayef A Abouzaki, Dave Dixon, Dinesh Kadariya, Sanah Christopher,[...]. Circ Heart Fail 2017
106
9

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].
Antonio Abbate, Benjamin Wallace Van Tassell, Giuseppe Biondi-Zoccai, Michael Christopher Kontos, John Dallas Grizzard, Debra Whittaker Spillman, Claudia Oddi, Charlotte Susan Roberts, Ryan David Melchior, George Herman Mueller,[...]. Am J Cardiol 2013
233
9

Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice.
Delphine Gomez, Richard A Baylis, Brittany G Durgin, Alexandra A C Newman, Gabriel F Alencar, Sidney Mahan, Cynthia St Hilaire, Werner Müller, Ari Waisman, Sheila E Francis,[...]. Nat Med 2018
115
9

Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis.
Amélie Vromman, Victoria Ruvkun, Eugenia Shvartz, Gregory Wojtkiewicz, Gustavo Santos Masson, Yevgenia Tesmenitsky, Eduardo Folco, Hermann Gram, Matthias Nahrendorf, Filip K Swirski,[...]. Eur Heart J 2019
54
14

The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.
Øystein Sandanger, Trine Ranheim, Leif Erik Vinge, Marte Bliksøen, Katrine Alfsnes, Alexandra V Finsen, Christen P Dahl, Erik T Askevold, Geir Florholmen, Geir Christensen,[...]. Cardiovasc Res 2013
284
9

Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction.
Antonio Abbate, Cory R Trankle, Leo F Buckley, Michael J Lipinski, Darryn Appleton, Dinesh Kadariya, Justin M Canada, Salvatore Carbone, Charlotte S Roberts, Nayef Abouzaki,[...]. J Am Heart Assoc 2020
58
13


Inflammasomes: mechanism of assembly, regulation and signalling.
Petr Broz, Vishva M Dixit. Nat Rev Immunol 2016
9


2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
8


Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury.
Masanori Kawaguchi, Masafumi Takahashi, Takeki Hata, Yuichiro Kashima, Fumitake Usui, Hajime Morimoto, Atsushi Izawa, Yasuko Takahashi, Junya Masumoto, Jun Koyama,[...]. Circulation 2011
519
8

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
Stephen Kaptoge, Emanuele Di Angelantonio, Gordon Lowe, Mark B Pepys, Simon G Thompson, Rory Collins, John Danesh. Lancet 2010
8

The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse.
Stefano Toldo, Adolfo Gabriele Mauro, Zachary Cutter, Benjamin W Van Tassell, Eleonora Mezzaroma, Marco Giuseppe Del Buono, Andrea Prestamburgo, Nicola Potere, Antonio Abbate. J Cardiovasc Pharmacol 2019
46
15

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
8

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Erin A Bohula, Robert P Giugliano, Christopher P Cannon, Jing Zhou, Sabina A Murphy, Jennifer A White, Andrew M Tershakovec, Michael A Blazing, Eugene Braunwald. Circulation 2015
186
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.